Abstract
Given that many skin disorders have an immunologic basis or involve inflammatory reactions, compounds affecting the afferent or the effector limbs of immune responses play a central role in dermatologic therapy. Topical glu-cocorticosteroids (GCs) represent the mainstay of anti-inflammatory and im-munosuppressive treatment of inflammatory skin diseases. However, despite their broad and common usage, some mechanisms by which GCs exert their functions still remain obscure. It is thought that binding of a GC to a cyto-plasmic glucocorticosteroid receptor (GCR) [65] leads to dissociation of a complex composed of a GCR and two heat-shock proteins [51]. This dissociation is followed by migration of the GCR-GC complex into the nucleus and binding to specific DNA sites called glucocorticoid response elements (GC-REs). A number of genes have been identified that are regulated by GC-REs, including lipocortin-1, an inhibitor of phospholipase A2 [22]. In addition, there is evidence that GCs can directly inhibit phospholipase A2 [51]. Both direct and indirect effects on phospholipase A2 synergistically decrease mediators of inflammation such as thromboxanes, prostaglandins, and leuko-trienes, thus inhibiting leukocyte attraction to sites of inflammation [27, 28].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H (1995) Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 133:494-496
Arnaout MA, Wang EA, Clark SC, Sieff CA (1986) Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 78:597-601
Auphan N, Didonato JA, Rosette C (1995) Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-290
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticosteroids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-287
Baker D, Kimber I, Turk JL (1989) Antigen-specific regulation of T lymphocyte prolif-erative responses to contact-sensitizing chemicals in the guinea pig. Cell Immunol 119:153-159
Barker JN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ (1990) Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 85:605-608
Barton BE, Jakway JP, Smith SR et al. (1991) Cyxtokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 13:251-261
Basketter DA, Bremmer JN, Buckley P, Kammuller ME, Kawabata T, Kimber I, Loveless SE, Magda S, Stringer DA, Vohr HW (1995) Pathology considerations for, and subsequent risk assessment of chemicals identified as immunosuppressive in routine toxicology. Food Chem Toxicol 33:239-243
Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD (1995) Kinetics and regulation of human keratinocyte stem cell growth in short term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T-lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95:317-323
Bos JD, Kapsenberg ML, Smitt JH (1994) Pathogenesis of atopic eczema. Lancet 343: 1338-1341
Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ (1998) The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 4:92-96
Christophers E, Sterry W (1993) Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freed-berg IM, Austen KF (eds) Dermatology in general medicine, vol 1. McGraw-Hill Inc. New York pp 489-514
Cooper KD (1994) Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 102:128-137
Cornell RC, Stoughton RB (1984) The use of topical steroids in psoriasis. Dermatol Clin 2:397-409
Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-1146
Dorfman A, Schiller S (1958) Effect of hormones on the metabolism of mucopolysac-charide of connective tissue. Recent Prog Horm Res 14:427
Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by IL-1 and interferon gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137:245-250
Eedy DJ, Burrows D, Bridges JM, Jones FGC (1990) Clearance of severe psoriasis after allogeneic bone marrow transplantation. BMJ 300:908
Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM, Turcotte JG, Voorhees JJ (1986) Cyclo-sporine improves psoriasis in a double-blind study. JAMA 256:3110-3116
Enk AH, Katz SI (1995) Contact sensitivity as a model for T-cell activation in skin. J Invest Dermatol 105:80S-83S
European FK506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double blind, placebo-controlled study. Arch Dermatol 132:419-423
Flower RJ, Rothwell NJ (1994) Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci 15:65-80
Frater-Schröder M, Risau W, Hallmann R, Gautschi P, Bohlen P (1987) Tumor necrosis factor type a, a potent inhibitor of endothelial growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 84:5277-5281
Gardembas-Pain M, Ifrah N (1990) Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 126:1523
Gleichmann E, Kimber I, Purchase IF (1989) Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion. Arch Toxicol 63:257-260
Gottlieb JL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442-447
Goulding NJ, Guyre PM (1992) Regulation of inflammation by lipocortin-1. Immunol Today 13:295-297
Goulding NJ, Guyre PM (1993) Glucocorticoids, lipocortins and the immune system. Curr Opin Immunol 5:108-113
Griffiths CEM, Voorhees JJ, Nickoloff BJ (1989) Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20:617-629
Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB (1989) Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 86:6367-6371
Homey B, Vohr HW, Schuppe HC, Kind P (1995) UV-dependent local lymph node reactions: photoallergy and phototoxicity testing. Curr Probl Dermatol 22:44-50
Homey B, Schuppe HC, Assmann T, Vohr HW, Lauerma AI, Ruzicka T, Lehmann P (1997) A local lymph node assay to analyse effects of topically applied drugs. Eur J Pharmacol 325:199-207
Homey B, Assmann T, Ulrich P, Vohr HW, Lauerma AI, Ruzicka T, Lehmann P, Schuppe HC (1998) Topical FK506: suppression of Thl and Th2 cytokine induction in lymph node cells in vivo. J Immunol 160:5331-5340
Kimber I (1994) Cytokines and regulation of allergic sensitization to chemicals. Toxicology 93:1-11
Kimber I, Weisenberger C (1989) A murine local lymph node assay for the identification of contact allergens. Assay development and results of an initial validation study. Arch Toxicol 63:274-282
Kimber I, Dearman RJ, Scholes EW, Basketter DA (1994) The local lymph node assay: developments and applications. Toxicology 93:13-31
Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H (1987) FK506, a novel immunosuppressant isolated from a Strepto-myces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 40:1256-1265
Koivukangas V, Karvonen J, Risteli J et al. (1995) Topical mometasone furoate and beta-methasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 132:66-68
Kripke ML, Munn CG, Jeevan A, Tang J-M, Bucana C (1990) Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 145:2838-2843
Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW (1995) IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 99:148-154
Marcusson J (1978) Psoriasis and arthritic lesions in relation to the inheritance of HLA genotypes. Acta Derm Venereol Suppl (Stockh) 59:1-48
Meingassner JG, Stütz A (1992. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851-855
Michel G, Mirmohammadsadegh A, Olasz E, Jarzebska-Deussen B, Müschen A, Kemeny L, Abts HF, Ruzicka T (1997) Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol 159:6291-6297
Mirmohammadsadegh A, Homey B, Abts HF, Köhrer K, Ruzicka T, Michel G (1998) Differential modulation of pro- and anti-inflammatory cytokine receptors by A77 1726, the physiologically active metabolite of the novel immunomodulator leflunomide. Biochem Pharmacol (in press)
Morikawa K, Oseko F, Morikawa S, Iwamoto K (1994) Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T lymphocyte function in vitro. Antimicrob Agents Chemother 38:2643-2649
Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD (1993) CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodefÃcient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 178:237-244
Mueller W, Herrmann B (1979) Cyclosporin A for psoriasis. N Engl J Med 301:555
Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, Harada S (1994) Tacrolimus ointment for atopic dermatitis. Lancet 344:883
Ning Y-M, Sanchez ER (1993) Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J Biol Chem 268:6073-6076
Powrie F, Leach MW, Mauze S, Caddie LB, Coffman RL (1993) Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol 5:1461-1471
Prakash A, Benfield P (1998) Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 55:145-163
Prinz J, Braun-Falco 0, Meurer M, Daddona P, Reiter C, Rieber P, Riethmuller G (1991) Chimaeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet 338:320-321
Rao A (1994) NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today 15:274-276
Russell TJ, Schultes LM, Kuban DJ (1972) Histocompatibility (HLA) antigens associated with psoriasis. N Engl J Med 287:738-740
Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska J, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337:816-821
Sarnstrand B, Brattsand R, Malmstrom A (1982) Effect of glucocorticoids on glycosami-noglycan metabolism in cultured skin fìbroblasts. J Invest Dermatol 79:412-417
Scheinman RI, Cogswell PC, Lofquist AK et al. (1995) Role of transcriptional activation of IκB in mediation of immunosuppression by glucocorticosteroids. Science 270:283-286
Schön MP, Parker CM (1997) A T cell initiated murine model of inflammatory skin lesions. Retinoids Lipid-soluble Vit Clin Prac. 13:128-131
Schön MP, Detmar M, Parker CM (1997) Murine psoriasis-like disorder induced by naive CD4+ T-cells. Nat Med 3:183-188
Schön MP, Detmar M, Parker CM (1997) Animal models of psoriasis (letter). Nat Med 3:476
Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-142
Schulz BS, Michel G, Wagner S, Suss R, Beetz A, Peter RU, Kemeny L, Ruzicka T (1993) Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK506 in vitro. J Immunol 151:4399-4406
Sigal NH, Dumont FJ (1992) Cyclosporine A, FK506 and rapamycin: pharmacological probes of lymphocyte signal transduction. Annu Rev Immunol 10:519-525
Snowden, JA, Heaton DC (1997) Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 137:130-132
Srivastava D, Thompson EB (1990) Two glucocorticoid binding sites on the human glucocorticoid receptor. Endocrinology 127:1770-1778
Stenmovic DU (1972) Corticosteroid-induced atrophy of the skin with teleangiectasia: a clinical and experimental study. Br J Dermatol 87:548-556
Subramanian N, Bray MA (1987) Interleukin 1 releases histamine from human baso-phils and mast cells in vitro. J Immunol 138:271-275
Swada S, Suzuk G, Kawase Y, Takaku F (1987) Novel immunosuppressive agent FK506: in vitro effects on the cloned Tcell activation. J Immunol 139:1797-1801
Theissen U, Luger TA, Schwarz T (1996) Successful treatment of pyoderma gangreno-sum by topical application of cyclosporin A. Hautarzt 47:132-135
Thomsen AW (1990) FK506 enters the clinic. Immunol Today 11:35-36
Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M (1980) Psoriasis and HLA-Cw6. Br J Dermatol 102:179
Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, Bowcock A (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264:1141-1145
Umland SP, Nahrebne DK, Razac S et al. (1996) Effects of mometasone furoate and other glucocorticoids on cytokine production from cultures peripheral blood CD4+ T cells (abstract). J Allergy Clin Immunol 97:289
Watson W, Cann HM, Farber EM, Nall ML (1972) The genetics of psoriasis. Arch Dermatol 105:197-207
White SH, Newcomer VD, Mickey MR, Terasaki PI (1972) Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med 287:740-743
Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887
Granlund H, Erkko P, Eriksson E, Reitamo S (1996) Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 76:371-376
Bangha E, Eisner P (1996) Evaluation of topical antipsoriatic treatment by chromame-try, visiometry and 20-MHz ultrasound in the psoriasis plaque test. Skin Pharmacol 9:298-306
Lofferer O, Reckers R (1978) Vergleichende Untersuchungen zur Wirksamkeit von Difli-cortolonvalerianat im Psoriasis-Plaque-Test. Arzneimittelrorschung 28:703-705
Wolff HH, Kreusch JF, Wilhelm KP, Klaus S (1993) The psoriasis plaque test and topical corticosteroids: evaluation by computerized laser profìlometry. Curr Prob Dermatol 21:107-113
Rappersberger K, Meingassner JG, Fialla R, Födinger D, Sterniczky B, Rauch S, Putz E, Stütz A, Wolff K (1996) Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 106:701-710
Ramsing DW, Agner T (1995) Efficacy of topical corticosteroids on irritant skin reactions. Contact Dermatitis 32:293-297
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schön, M.P., Homey, B., Ruzicka, T. (2000). Antiphlogistics (Dermocorticoids and topical immunomodulators). In: Gabard, B., Surber, C., Elsner, P., Treffel, P. (eds) Dermatopharmacology of Topical Preparations. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57145-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-57145-9_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62960-0
Online ISBN: 978-3-642-57145-9
eBook Packages: Springer Book Archive